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Cutting Edge: Species-Specific TLR9-Mediated
Recognition of CpG and Non-CpG
Phosphorothioate-Modified Oligonucleotides1
Tara L. Roberts,*† Matthew J. Sweet,*†‡ David A. Hume,*†§ and Katryn J. Stacey2*†‡
Different DNA motifs are required for optimal stimula-
tion of mouse and human immune cells by CpG oligode-
oxynucleotides (ODN). These species differences presum-
ably reflect sequence differences in TLR9, the CpG DNA
receptor. In this study, we show that this sequence speci-
ficity is restricted to phosphorothioate (PS)-modified
ODN and is not observed when a natural phosphodiester
backbone is used. Thus, human and mouse cells have not
evolved to recognize different CpG motifs in natural
DNA. Nonoptimal PS-ODN (i.e., mouse CpG motif on
human cells and vice versa) gave delayed and less sus-
tained phosphorylation of p38 MAPK than optimal mo-
tifs. When the CpG dinucleotide was inverted to GC in
each ODN, some residual activity of the PS-ODNwas re-
tained in a species-specific, TLR-9-dependent manner.
Thus, TLR9 may be responsible for mediating many pub-
lished CpG-independent responses to PS-ODN. The
Journal of Immunology, 2005, 174: 605–608.
B acterial DNA is recognized by cells of the innate im-mune system by the presence of unmethylated CGdinucleotides in particular sequence contexts (CpG
motifs) (1, 2). Cellular responses to CpG DNA require initial
internalization of the DNA followed by endosomal acidifica-
tion (3–5). The CpG motif is then recognized and signaling is
initiated via TLR9 (6).
Responses to bacterial DNA are mimicked by oligode-
oxynucleotides (ODN)3 containing a CpG motif. Immunos-
timulatory ODN have potential applications in cancer and al-
lergy therapy and as vaccine adjuvants (7). In these in vivo
applications nuclease-resistant phosphorothioate (PS)-ODN
are used. In the PS modification, one of the nonbridging oxy-
gens in the backbone is replaced by sulfur. Much of the work
examining the immune response to CpG DNA has used only
PS-ODN. PS-ODNhave been reported to have CpG-indepen-
dent effects on B cell proliferation, Ab production and IL-6 pro-
duction (8–10), and macrophage chemotaxis (11) and in vivo
to induce splenomegaly and infiltration of tissues by mononu-
clear cells (9). The mechanisms responsible for non-CpG-re-
lated effects of PS-ODN have not been characterized.
Mice and humans respond preferentially to different CpG-
containing PS-ODN (12, 13). The optimal mouse motif
is purine-purine-C-G-pyrimidine-pyrimidine; GACGTT and
AACGTT are most commonly used. For humans, GTCGTT
in multiple copies, separated by TT dinucleotides is optimal.
HEK293 cells transfected with human TLR9 respond prefer-
entially to the human motif, but when transfected with mouse
TLR9 are more sensitive to the mouse motif (14–16). This
suggests that TLR9 itself directly interacts with DNA and me-
diates species-specific binding. These studies were performed
exclusively using PS-ODN.Direct CpG-dependent interaction
of PO-ODN with TLR9 has recently been confirmed (17).
However, the binding affinity of TLR9 for phosphodiester
(PO)-ODN of different sequences did not correlate with the
established species-specific responses to PS-ODN. In this arti-
cle, we show that species-specificity for recognition of stimula-
tory sequences is restricted to PS-ODN and that TLR9 can
mediate responses to non-CpG PS-ODN.
Materials and Methods
Cells and mice
The mouse macrophage cell line RAW264.7 and human B cell line RPMI8226
were purchased from the American Type Tissue Culture Collection.WEHI231
mouse B cells were a gift from D. Tarlinton (Walter and Eliza Hall Institute,
Melbourne, Australia). Medium used was RPMI 1640 with 10% FCS, 2 mM
L-glutamine, 20 U/ml penicillin, and 20 g/ml streptomycin. TLR9 knockout
mice, obtained from Shizuo Akira (Research Institute for Microbial Diseases),
were bred from heterozygotes and wild-type siblings were used as controls. To
obtain splenocytes, spleens were homogenized through a tea strainer and a sin-
gle-cell suspension generated by passage through an 18-gauge needle. PBMCs
were obtained from fresh human blood and collected into heparinized tubes.
Ficoll-Paque (Amersham Biosciences) solution was layered under whole blood
diluted 1/4 with saline and samples centrifuged at 400  g for 15–20 min.
PBMCs at the interface were removed and washed twice with PBS with cen-
trifugation at 500 g for 10 min at 10°C. PBMCs were used immediately.
Oligonucleotides
PS- and PO-ODNwere obtained fromGeneworks. PS-ODNused were: 1668,
TCCATGACGTTCCTGATGCT (1); 2006, TCGTCGTTTTGTCGTTT
TGTCGTT (12); 1826, TCCATGACGTTCCTGACGTT (18); 1668-GC,
TCCATGAGCTTCCTGATGCT; 2006-GC, TGCTGCTTTTGTGCTTT
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TGTGCTT. The PO-ODNversions of 1668 and 2006 are designated 1668-O
and 2006-O.
ELAM promoter assay
The mouse macrophage cell line RAW264.7 stably transfected with the human
NF-B-responsive ELAM promoter driving expression of enhanced GFP,
termed ELAM9, has been described (19). ELAM9 cells were treated with indi-
cated amount of DNA for 4–6 h before harvesting for analysis of GFP expres-
sion by flow cytometry as described previously (19).
ELISA
Two hundred fifty thousand cells per well were plated in 250 l of complete
medium and treated with DNA for 24 h. ELISA was performed using paired
Abs against human and mouse IL-6 (BD Pharmingen) as described previ-
ously (20).
Western blotting
Cells were lysed in boiling 66mMTris-HCl (pH 7.4) plus 2% SDSwith 1mM
sodium pyrophosphate, 10 mM sodium fluoride, 1 mM sodium molybdate,
and 1 mM sodium vanadate as phosphatase inhibitors. Western blotting was
performed as described elsewhere (21), and p38 or its activated form phosphor-
ylated on threonine 180 and tyrosine 182 were detected using Abs from Cell
Signaling Technology.
Results and Discussion
Species specificity is restricted to PS-ODN
We examined mouse and human motifs as both PS- and PO-
ODN in activation of human and mouse cells. 1668 and 2006
are PS-ODN containing the optimal mouse and humanmotifs,
respectively. 1668 was more active than 2006 in assays of acti-
vation of a mouse macrophage cell line, mouse WEHI231 B
cells and mouse splenocytes (Fig. 1, A–C). The converse was
true for IL-6 production from human PBMCs where the hu-
man motif in 2006 had superior activity at low concentrations,
although both sequences gave the same response above 1 M
(Fig. 1D). Unexpectedly, the corresponding PO-ODN,
1668-O and 2006-O had identical activity on all cells (Fig. 1).
The measured IL-6 produced by splenocytes and PBMCs in re-
sponse to PO-ODN was very low. However, in four separate
experiments on PBMCs, IL-6 levels in response to PO-ODN
were at least four times the detection limit and there was no
difference between the activities of mouse and human motifs.
The fact that species-specific CpG responses are restricted to
PS-ODN has not been widely appreciated. A recent report
showed that mouse TLR9-transfected HEK293 cells gave a
similar response to 2006-O and 1668-O at a single high con-
centration of 10 M (17). In our experience, assessment of the
potency of CpG motifs requires analysis at a range of concen-
trations, since poorly activating sequences such as cytosine-
methylated CpG motifs can attain the same level of activation
as optimal motifs if the concentration is high enough (result not
shown).
TLR9 recognition of DNA
Binding data in Biacore studies has clearly shown CpG-specific
binding of PO-ODN to TLR9 (17). Binding to a PO version of
1668 was much more rapid and reached a higher level than its
GC inversion. Interestingly, TLR9 bound only to single
stranded molecules, suggesting that DNA strand separation in
the endosome is an obligatory step for recognition of CpGmo-
tifs within dsDNA. Binding was dependent on acid pH, con-
sistent with the requirement for endosomal maturation in re-
sponses to CpG DNA. In contrast to expectations, mouse
TLR9 interacted more strongly with PO-ODN containing hu-
man motifs, such as 2006-O, than 1668-O (17). Our results
here show clearly in a number of different cell types that these
two PO-ODN have indistinguishable activity (Fig. 1). There
could be a number of explanations for the discrepancy between
TLR9 binding and activity. It cannot be assumed that the mea-
sured rate of ODN binding to TLR9 in vitro is the sole deter-
minant of TLR9 activation. An affinity for TLR9 is an obvious
prerequisite for activity, but an antagonist may well have higher
affinity. It is likely that the conformation adopted by the ODN
upon TLR9 binding and ability to induce conformational
FIGURE 1. Species specificity for CpGmotif recognition is restricted to PS-
ODN. 1668 contains the mouse motif and 2006 efficiently activates human
cells. They were tested as PS and PO versions on mouse and human cells. A,
Activation of the ELAM promoter in mouse macrophages stably transfected
with an ELAM promoter-GFP construct. Each point is the average of dupli-
cates and error bars show the values obtained. The experiment is representative
of four independent assays. B, IL-6 production by the mouse B cell line
WEHI231. Each point is the average of triplicates and error bars show the SD.
The experiment is representative of two independent assays.C, IL-6 production
by mouse splenocytes. Splenocytes were isolated from CD1mice, left for 2 h in
culture, and then treated with ODN for 24 h. Each point is the average of
triplicates and error bars indicate the SD. The experiment is representative of
two independent assays. D, IL-6 production by human PBMCs. Each point is
the average of triplicates and error bars indicate the SD. The experiment is rep-
resentative of two independent assays.
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change in TLR9 are important. Alternatively, binding condi-
tions in in vitro experiments may not adequately replicate the
endosomal environment, other interacting proteins may be re-
quired or the pH or chemical environment may not be optimal.
Nonoptimal PS-ODN give delayed and reduced signaling
We previously showed that signaling in response to a PS-ODN
was delayed compared with its PO-ODN counterpart (21).
More recent results demonstrated that this delay is not seen
with PS-ODN 1668, and hence is sequence dependent (result
not shown).Mouse and humanmotifs may therefore vary in the
rapidity with which they activate different cell types. We com-
pared the kinetics of induction of p38 phosphorylation in re-
sponse to mouse and human ODN by Western blotting. In
both mouseWEHI231 B cells and the mouse RAW264.7 mac-
rophage cell line, PS-ODN containing the mouse motif (1668
or 1826) induced earlier and more sustained phosphorylation
than the human ODN 2006 (Fig. 2, A and B), consistent with
the more effective response to the mouse motif. Conversely, in
the human B cell line RPMI8226, 2006 induced phosphoryla-
tion earlier than 1668 (Fig. 2C). In general, we found signaling
in humanRPMI8226 cells to be slower than that ofmouse cells,
even with optimal motifs. In other experiments, no p38 phos-
phorylation was seen after 30 min of exposure to 2006 (result
not shown). This may be related to the apparent lower affinity
of human TLR9 for DNA (17).
The relative activity of mouse and humanmotifs in cells from
each species was thus a result of more rapid and more sustained
signaling in response to the preferred motif (Fig. 2). We have
found no difference in the rate of uptake or the intracellular
trafficking of fluorescently labeled 2006 and 1668 that could
explain the observed differences in activity (result not shown).
The delayed signaling in response to nonoptimal motifs is likely
to be due to either a reduced affinity for TLR9 or a structural
conformation of bound ODN which is not optimal for TLR9
activation.
PS modification may constrain TLR9 binding
The PS modification replaces oxygen in the PO backbone with
the larger sulfur atom. This may restrict the conformations
available to PS-ODN within a putative DNA binding groove
on TLR9. Conformations adopted to accommodate the sulfur
atommay not allow certain base sequences to fit well within the
binding site. Consistent with this, the sequence requirements
for activity of PS-ODNare known to bemore stringent than for
PO-ODN (7). Some active PO-ODN become inactive when
PS modified (12). Elucidation of the basis of species-specific
PS-ODN recognition requires greater understanding of the
structural basis for CpG DNA interaction with TLR9.
GC ODN also show species-specific activity
The inversion of the CpGs within 2006 and 1668 to GC did
not completely prevent their activity, and the residual activity of
GC inversions retained the species specificity of the parent
ODN (Fig. 3). On mouse WEHI231 B cells (Fig. 3A) and
RAW264.7 macrophage-like cells (result not shown), the GC
inversion of 1668 had readily detectable activity, while
2006-GC was inactive. In human cells, the sequence specificity
was less absolute; both GC inversions had activity on the
RPMI8226 human B cell line, although 2006-GC activity was
detectable at lower concentrations (Fig. 3B). The response to
2006-GC reached a maximum and then declined with increas-
ing concentration. The phenomenon of “self inhibition” by PS-
ODN at higher concentrations has been observed before (21)
and is sequence dependent because it is more pronounced with
FIGURE 2. Nonoptimal PS-ODN give delayed signaling. Western blots
were performed to detect the phosphorylated form of p38 at various times after
the addition of PS-ODN. A,WEHI231 mouse B cells were treated with 1 M
1668 or 2006. Blotting for total p38 was used for loading control. B,
RAW264.7 mouse macrophage cells were treated with 1 Mmouse (1826) or
human (2006) ODN. Blotting for total p38 was used for loading control. C,
RPMI8226 human B cells were treated with 1M1668 or 2006. Protein assay
was used to ensure equal amounts of protein were loaded.
FIGURE 3. GC inversions of mouse and human CpG PS-ODN show re-
sidual species-specific activity. A, IL-6 induced in mouse WEHI231 B cells.
Each point is the average of triplicates and error bars show the SD. The exper-
iment is representative of two independent assays. B, IL-6 induced in human
RPMI8226 B cells. Each point is the average of triplicates and error bars show
the SD. The experiment is representative of two independent assays.
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certain PS-ODN. CpG-free PS-ODN rich in thymidine resi-
dues can activate human B cells (22, 23). The T-rich nature of
2006 may be important for its high activity on human cells and
may be responsible for responses to 2006-GC at low concen-
trations. Human cells showed less discrimination between CpG
and GC ODN than mouse cells did. In human RPMI8226
cells, induction of IL-6 by 2006-GCwas 15%of the response to
2006 (result not shown). For activation of the ELAM promoter
in a mouse macrophage cell line or IL-6 induction in mouse
WEHI231 cells, responses to 1668-GC reached 5% of the
value for 1668 (result not shown).
GC ODN activity is dependent on TLR9
Given that the species specificity for CpGPS-ODN ismediated
by TLR9 (14), TLR9 is likely to be required for the residual
species-specific response to the GC inverted ODN. To confirm
this, splenocytes were isolated from TLR9 knockout mice and
wild-type littermates. Wild-type splenocytes produced IL-6 in
response to 1668-GC but not 2006-GC (Fig. 4). Splenocytes
from TLR9/ mice had no response to non-CpG PS-ODN
(Fig. 4) or CpG ODN (result not shown). Thus, the induction
of IL-6 in response to GC PS-ODN also requires the presence
of TLR9. A recent article has shown similar TLR9 dependence
for Ab production in response to non-CpG PS-ODN (10). Re-
sponses to non-CpG PS-ODN are not just sequence-indepen-
dent responses to the PS backbone as some sequences are inac-
tive. It is likely that many of the reported immunostimulatory
responses to non-CpG PS-ODN of various sequences (8, 9, 11,
22, 23) are mediated through TLR9.
Conclusion
Species specificity for CpGmotif recognition is a necessary con-
cern in therapy, where PS-ODN are used, and is also a useful
tool for studying TLR9-mediated activation. However, our
work here suggests that human and mouse TLR9 have not
evolved to recognize different CpG motifs in natural DNA.
Species specificity for CpG motifs is not relevant to the in vivo
response to infection nor to plasmid-based DNA vaccination,
since in both cases the DNA presented to the immune system
would have the native PO backbone. There would conse-
quently be no expectation that mouse and human viruses or
other pathogens have differentially suppressed “mouse” and
“human” CpG motifs in their genomes.
Inversion of the CpG dinucleotide in mouse and human PS-
ODN left residual TLR9-dependent, species-specific re-
sponses. Thus, many reported immunostimulatory responses to
non-CpG PS-ODN may also be mediated through TLR9. For
applications such as antisense therapy, which use PS-ODN,
avoiding immune stimulation may not be as simple as just
avoiding CpG motifs. CpG-independent immunostimulatory
activity of PS-ODN will probably depend on the ability of the
PS-ODN to fit within the binding pocket of TLR9 and par-
tially mimic the structure adopted by efficient CpG-containing
ligands.
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FIGURE 4. TLR9 is required for the response to non-CpG-containing
ODN. Splenocytes from TLR9/ knockout mice and wild-type littermates
were left overnight in culture and then treated with various concentrations of
human and mouse GC-inversion PS-ODN (2006-GC and 1668-GC, respec-
tively). Each point is the average of duplicates and error bars indicate the values
obtained. The experiment is representative of two independent assays.
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